Duodenal Ulcer, Early Gastric Cancer, Gastric Mucosa-associated Lymphoid Tissue (MALT), Gastric Ulcer, Lymphoma Idiopathic Thrombocytopenic Purpura
Conditions
Keywords
triple therapy, Helicobacter pylori, eradication, Nexium
Brief summary
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.
Detailed description
Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer
Exclusion criteria
\- H.pylori negative at the time when the triple therapy is started
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Adverse Drug Reactions | Period from the start of triple therapy to assessment of eradication, an expected average of 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Rate of H.Pylori eradication | Period from the start of triple therapy to assessment of eradication, an expected average of 3 months |
Countries
Japan
Outcome results
None listed